Summary: In a 52-week placebo-controlled trial in women with type 2 diabetes, sitagliptin preserved total hip bone density, which declined significantly on placebo, but had no consistent effect at other skeletal sites or on bone turnover markers.
PICO Summary
| Element | Detail |
|---|---|
| Population | 132 women with type 2 diabetes on metformin with stable control; phase III, double-blind, placebo-controlled RCT, Italy. |
| Intervention | Sitagliptin for 52 weeks. |
| Comparison | Placebo for 52 weeks. |
| Outcome | Sitagliptin preserved total proximal femur (hip) BMD T score (change -0.02; p=0.46), whereas placebo declined significantly (-0.13; p<0.0001); the between-group difference favoured sitagliptin (0.11; 95% CI 0.03–0.19; p=0.0063). No significant effects at other sites or on turnover markers. Sitagliptin reduced inflammatory mediators of bone metabolism. Glucose control did not differ. |
SLowDOWN: Sitagliptin and Bone Density
RCT · type 2 diabetes · 52 weeks
Sitagliptin preserved total hip bone density over 52 weeks while it fell on placebo, a small but significant between-group difference confined to the hip.
Expert Commentary
This is a well-designed and clinically thoughtful trial that addresses the diabetes bone paradox, where fracture risk is elevated despite often-normal density, and it is careful in what it claims. The defensible message is preservation rather than improvement: sitagliptin held hip density steady while placebo fell, and the hip is the site that matters most given the morbidity and mortality of hip fracture. The incretin rationale is sound, since GIP and GLP-1 preserved by DPP-4 inhibition have actions on osteoblasts and osteoclasts, and the parallel fall in inflammatory mediators is mechanistically consistent. I would respect the limits the data impose: the effect was confined to the hip with no change at other sites or in turnover markers, density is a surrogate rather than a fracture endpoint, the trial enrolled only 132 women over a year, and even the investigators acknowledge the need for confirmation in higher-risk populations. Can I use this with my patients? As a tie-breaker, not a treatment. For a postmenopausal woman with diabetes and skeletal risk needing therapy intensification, this modestly favours a DPP-4 inhibitor over bone-adverse options like thiazolidinediones, while glycaemic and cardiorenal priorities still lead, and established osteoporosis drugs remain the answer when treatment is actually indicated.
References
Barchetta I, Filardi T, Dule S, et al. Effect of sitagliptin vs. placebo on bone mineralization in women with type 2 diabetes: the SLowDOWN (SitagLiptin in Diabetes for Osteoporosis in WomeN) randomized clinical trial. BMC Med. 2025;23(1):562. doi:10.1186/s12916-025-04363-w